177Lu-trastuzumab

77Lu-trastuzumab represents an investigational radiopharmaceutical that combines the monoclonal antibody trastuzumab with Lutetium-177 (177Lu). Trastuzumab, also known as Herceptin, specifically targets the human epidermal growth factor receptor 2 (HER2), which is overexpressed in certain types of cancer, particularly breast cancer.

Virtual price, please inquire if needed.

We can mass produce (kg level),process scaling up, pilot supply,raw material supply, and intermediate production. Our production technology is mature and more cost-effective. Feel free to inquire at any time.

msds of 177Lu-trastuzumab